Scholars Central

Conference abstractPublished 28 Sep 2015

Pharmaco-dynamic of peptide HM-3 and its effect on HCT-116 tumor micro-environment

Authors: Sitelbanat Yassin, Han- Mei Xu, Jia-Liang Hu, Jun-Jing He, Ce Li, Sarra Setrerrahmane

1Department of Life Science and Technology, China Pharmaceutical University, People Republic of China 2Department of pharmaceutics, Faculty of Pharmacy, University of Gezira, Sudan

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

A novel antitumor polypeptide HM-3 is an integrin receptor antagonist composed of eighteen amino acids and contained integrin targeting sequence RGD. Based on the fact, the peptide HM-3 had good In vitro results against HCT-116 tumor cell line. The present study was done for determination of In vivo dose effect relationship of HM-3 against HCT-116 cell line and its interactions with the tumor micro-environments. In vivo image was done in BALB/c-nu nude mice which showed this peptide not only distributed in the GIT, breast, limb and lung but also in the tumor mass. Furthermore, HM-3 was evaluated against HCT-116 cell xenografted in BALB/c-nu nude mice. The results exhibited that HM-3 (3 mg/kg) had an excellent inhibitory effect against HCT-116 cell with the inhibition rate of 71.5%, similar to Sunitinib (60 mg/kg) which was 72%. Moreover, immunohistochemstry (IHC) analysis for the extracted tumor of the mice treated with HM-3 (3 mg/kg) and the negative control group showed that HM-3 reduced HIF1-Ã?±, VEGF, CD105-MVD and CD31-MVD. In conclusion, FITCHM- 3 accumulated within the tumor mass that was confirmed by the in vivo image. However, the research history of integrin antagonists was relatively short and the researchers may not notice the specific dose-efficacy relationship of these drugs, the effective dose was accurately defined and the interactions between HM-3 and tumor micro-environments were determined immunohistochemically. This study provided an important reference for clinical applications of HM-3, which is worth for future use as a therapeutic drug for treatment of colorectal cancer solid tumor of HCT-116.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Cancer Science & Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalCancer Science & Therapy
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Sitelbanat Yassin”
  • BylineArticles whose byline prints “Han- Mei Xu”
  • BylineArticles whose byline prints “Jia-Liang Hu”
  • BylineArticles whose byline prints “Jun-Jing He”
  • BylineArticles whose byline prints “Ce Li”
  • BylineArticles whose byline prints “Sarra Setrerrahmane”